SCHEDULE OF LIVE WEBINAR ON “STRENGTHENING BLOOD SYSTEMS THROUGH EFFECTIVE BLOOD REGULATION”
(WITH SIMULTANEOUS TRANSLATION INTO SIX WHO OFFICIAL LANGUAGES)
4 days, 3 hours per-day, 4 topics per-day
03-06 August 2020
WHO Related Material Time Proposed
Topic Allocation Speakers
(Min)
Day 1, 3 August 2020, start at 13.00 CET
Opening 5 WHO
1. Current Issues in development of blood and blood products/The Value of 55 WHO Consultant
Blood and Blood Product and Elements of a National Blood Policy (WHO Jay Epstein
Guidance) -
https://www.who.int/bloodsafety/transfusion_services/nat_blood_pol/en
/
40 EMRO
2. Review of Blood Regulatory Framework (EMRO experience) Yetmgetta Abdella
ts for blood systems of countries in the WHO EMR.pdf
40 BRN
3. Functions of the blood regulator (prototype GBT, WHO Assessment Micha Nuebling
Criteria) GBT+ (as available)
odRegSystems.pdf
Questions and answers of Day 1 40 Moderator
Day 2, 4 August 2020, start at 13.00 CET
35 BRN
4. GMP for Blood Establishments Christian Schaerer
GMP_Bloodestablish
ments.pdf
5. Regulation of blood/blood components as essential medicines 35 BRN
http://apps.who.int/medicinedocs/en/m/abstract/Js23322en/ Francisca Agbanyo
6. Blood product standards 35 AABB
https://www.afsbt.org/images/accreditation_documents/AfSBT_Step_Wis Jed Gorlin
e_Accreditation_Standards.pdf
35 AABB
7. Product testing Jed Gorlin
https://www.who.int/ihr/publications/lqms/en/
9789241548274_eng.
pdf
Questions and answers of Day 2 40 Moderator
Day 3, 5 August 2020, start at 13.00 CET
8. Conduct of inspections 35 BRN
https://www.who.int/medicines/areas/quality_safety/quality_assurance/Q Christian Schaerer
ualitySystemRequirementsNationalGMPInspectoratesTRS902Annex8.pdf?u
a=1
9. Prevention of Transfusion Transmissible Infections 40 BRN
Selection of donors Micha Nuebling
https://www.who.int/bloodsafety/ScreeningTTI.pdf
10. Prevention of Transfusion Transmissible Infections
Laboratory testing
https://www.who.int/ihr/publications/lqms/en/
11. Elements of a hemovigilance system 35 IHN
https://www.who.int/bloodsafety/haemovigilance/haemovigilance- Jo Wiersum (recorded
guide/en/ presentation)
https://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf
Questions and answers of Day 3 40 Moderator
Day 4, 6 August 2020, start at 13.00 CET
60 Region/Country
12. Region/Country presentation (10 minutes each)
75 PEI Blood Train
13. Practical exercises (case studies) a. Jens Reinhardt
a. Criteria for blood establishment qualification b. Washington
b. Conduct of an inspection Samukange/Chancelar
Kafere
c. Joanna
c. Risk prevention: e.g. emerging TTID/IVD etc. Atemnkeng/Kristina
Heinrich/Herbert
Mbunkah
d. Principles of a Clinical trial concept for COVID-19 convalescent plasma d. Anneliese Hilger
Questions and answers Day 4 40 Moderator
Closing 5 WHO
Concept Note
WHO LIVE WEBINAR ON
STRENGTHENING BLOOD SYSTEMS THROUGH
EFFECTIVE BLOOD REGULATION
3-6 AUGUST 2020
Background
A blood product is any therapeutic substance derived from human blood, including whole blood
and other blood components for transfusion, and plasma derived medicinal products (PDMPs).
Safe, effective and quality assured blood products contribute to improving and saving millions of
lives every year. Access to blood products, which includes equitable availability and affordability,
is imperative to safeguard public health. However, a major imbalance exists between higher-
income and lower-income countries in access to safe, effective and quality assured blood products.
WHO is strongly committed to the improvement of blood product safety, effectiveness and quality,
and has provided a great number of guidelines, biological reference standards, training and
technical support in past decades. Still, progress in blood regulation and availability has been slow
in many parts of the world.
For that reason, the WHO Action framework to advance universal access to safe, effective and
quality-assured blood products 2020–2023 proposes a renewed effort to scale up programme
implementation and improve access to blood products. The first challenge in ensuring access to
safe blood products, that has been identified and listed in the Action framework is deficiencies in
national policy, governance and financing. The GDBS 2015 showed that only 60-70% Member
States reported the existence of a national blood regulatory framework, with regional variations.
Member States Barriers to a well-functioning national blood system include, lack of political
commitment and awareness of the essential role of a national blood system in the larger health
system; inadequate legal and regulatory frameworks for a national blood system; and resource
limitations. To address this challenge, an appropriately structured, well-coordinated and
sustainably resourced national blood system should be established. A webinar on this aspect is
needed to improve Member States knowledge and capacity to establish and sustain a national blood
system that is integrated into the national health system, with clearly defined roles and
accountabilities, and regulatory decision-making and governance frameworks.
Objectives and Goals
The Webinar is expected to improve country knowledge and capacity on how to strengthen blood
systems through effective blood regulation.
Page 1 of 2
During the live webinar the following topics/presentations are planned to be covered:
(1) The Value of Blood and Blood Product and Elements of a National Blood Policy
(2) Review of Blood Regulatory Framework: EMRO experience
(3) Functions of the blood regulator
(4) GMP for Blood Establishments
(5) Regulation of blood/blood components as essential medicines
(6) Blood product standards
(7) Product testing
(8) Conduct of inspections
(9) Prevention of Transfusion Transmissible Infections: a) selection of donors
(10) Prevention of Transfusion Transmissible Infections: b) laboratory testing
(11) Elements of a hemovigilance system
(12) Country experience in building blood regulation
Expected outcomes:
Blood regulators from each country in coordination with Blood Establishment will be able to
build effective blood regulation as an effort to strengthen national blood system.
Participants:
(1) Blood regulators officials from the Ministry of Health
(2) Responsible person for National Blood Programmes
(3) Directors of the major Blood Establishments
Webinar scenario:
This is a Four-day Live Webinar in English that will be translated simultaneously into all six WHO
official languages. The recordings of the webinar will be posted on the website. Each day, the
Webinar will start at 13.00 CET, with 4 topics in 3 hours.
The speakers are blood regulators from the Blood Regulators Network, as well as from American
Association of Blood Banks (AABB), International Haemovigilance Network (IHN) and Paul
Ehrlich Institute (PEI) Blood Train.
Page 2 of 2
ORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION Date: 17 July 2020
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONAL OFFICE FOR EUROPE Ms Elen Ohov
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA
Adviser
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co-
Head office:
operation Department
UN City, Marmorvej 51, Ministry of Social Affairs
DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected] Tallinn 10122
Website: http://www.euro.who.int Estonia
Email:
[email protected]
Dear Ms Ohov,
WHO live webinar on strengthening blood systems
through effective blood regulation
3–6 August 2020
We have the honour to inform you that the World Health Organization is holding a live webinar on
strengthening blood systems through effective blood regulation from 3 to 6 August 2020.
The speakers in the webinar are blood regulators from the Blood Regulators Network and from the
American Association of Blood Banks (AABB), the International Haemovigilance Network (IHN) and
the Paul-Ehrlich-Institute (PEI) BloodTrain.
The webinar language will be English, with simultaneous translation into the other five WHO official
languages. The recordings of the webinar and all relevant information will be posted on the website.
Each day, the webinar will start at 13:00 and end at 16:00 CET.
I have pleasure in inviting you to nominate three participants from your country, representing the
following institutions:
• blood regulatory official from the Ministry of Health
• person responsible for national blood programmes
• directors of the major blood establishments.
We look forward to receiving your nominations, stating the names, functional titles and contact details
(including e-mail address) of the proposed participants, at the latest by 27 July 2020. The required
information should be directed to Dorina Pirgari (
[email protected]), Health Technologies and
Pharmaceuticals Programme, WHO Regional Office for Europe. We will then communicate with the
participants directly and provide them with the necessary documentation and administrative information
in good time.
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
Should you have questions or need any further information, please do not hesitate to contact us.
Yours faithfully,
Dr Natasha Azzopardi Muscat
Director
Division of Country Health Policies and Systems
Copy for information to:
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs, Suur-Ameerika
1, Tallinn 10129, Estonia, Email:
[email protected],
[email protected]
H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative, Permanent
Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva, Chemin
du Petit-Saconnex 28A, Genève CH-1209, Switzerland, Email:
[email protected]
H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, agréé, Embassy of the Republic of
Estonia, Frederiksgade 19, 4th floor, Copenhagen K 1265, Denmark, Email:
[email protected]
Ms Marge Reinap, Head of WHO Office, a.i., WHO Country Office, Estonia, Paldiski Road 81, Tallinn 10617, Estonia,
Email:
[email protected],
[email protected]
–2–
Saatja: LINDHARDT, Lisbeth Sjaelborg <
[email protected]>
Saadetud: 20.07.2020 15:17
Adressaat: Elen Ohov <
[email protected]>
Koopia: Triin Uusberg <
[email protected]>; SM Info <
[email protected]>;
<
[email protected]>; <
[email protected]>; REINAP, Marge
<
[email protected]>; POLISHCHUK, Olexandr <
[email protected]>; PIRGARI,
Dorina <
[email protected]>; LINDHARDT, Lisbeth Sjaelborg
<
[email protected]>
Teema: EST WHO live webinar on strengthening blood systems 3-6 August
2020
Please see the attached correspondence sent from the World Health
Organization, Regional Office for Europe. One or more attachments may be
included.Veuillez vous r¨¦f¨¦rer ¨¤ la correspondance ci-jointe du Bureau
r¨¦gional de l'Europe de l'Organisation mondiale de la sant¨¦. Une ou
plusieurs annexes peuvent ¨ºtre jointes.Mit der Bitte um Kenntnisnahme
der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalb¨¹ro f¨¹r Europa.§³§Þ.
§á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§í§Ö §á§Ú§ã§î§Þ§Ñ §à§ä §¦§Ó§â§à§á§Ö§Û§ã§Ü§à§Ô§à
§â§Ö§Ô§Ú§à§ß§Ñ§Ý§î§ß§à§Ô§à §Ò§ð§â§à §£§ã§Ö§Þ§Ú§â§ß§à§Û
§à§â§Ô§Ñ§ß§Ú§Ù§Ñ§è§Ú§Ú §Ù§Õ§â§Ñ§Ó§à§à§ç§â§Ñ§ß§Ö§ß§Ú§ñ (§à§Õ§Ú§ß §Ú§Ý§Ú
§ß§Ö§ã§Ü§à§Ý§î§Ü§à §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§í§ç §æ§Ñ§Û§Ý§à§Ó).
Best regards,
Lisbeth Lindhardt
Health Technologies and Pharmaceuticals Programme
WHO Regional Office for Europe
Office 1.2.07
Ext 7 6764
HTP annual report 2019: